By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Neurocrine Biosciences, Inc. 

12790 El Camino Real

San Diego  California  92121  U.S.A.
Phone: 858-617-7600 Fax: 858-617-7601


Company News
Nothing's Gonna Stop Neurocrine Biosciences (NBIX) Now: Shares Jumped on FDA Approval of the First and Only Drug to Treat Tardive Dyskinesia for Adults 4/12/2017 7:00:55 AM
Neurocrine Biosciences (NBIX) Announces American Journal Of Psychiatry Publication Of Positive Results From Kinect 3 Phase III Study Of INGREZZA TM (Valbenazine) For The Treatment Of Tardive Dyskinesia 3/21/2017 7:31:49 AM
Neurocrine Biosciences (NBIX) Reports Year-End 2016 Results And Provides Investor Update For 2017 2/15/2017 8:09:05 AM
Neurocrine Biosciences (NBIX) Nabs North American Rights to Bial's ONGENTYS 2/10/2017 6:42:47 AM
Neurocrine Biosciences (NBIX) Announces Conference Call And Webcast To Report Fourth Quarter And Year-End 2016 Results 2/7/2017 6:32:47 AM
Neurocrine Biosciences (NBIX) Release: SoCal Biotech's Tourette Drug Flunks Phase II Study 1/18/2017 5:31:04 AM
Neurocrine Biosciences (NBIX) Announces The Appointment Of David-Alexandre Gros M.D. President And Chief Operating Officer 1/6/2017 8:24:50 AM
Neurocrine Biosciences (NBIX) Provides Update On FDA Advisory Committee For INGREZZA (Valbenazine) For The Treatment Of Tardive Dyskinesia 1/6/2017 7:55:59 AM
Neurocrine Biosciences (NBIX) Announces Chief Financial Officer Timothy P. Coughlin To Step Down 12/22/2016 12:39:45 PM
Neurocrine Biosciences (NBIX) Announces FDA Advisory Committee Meeting To Review INGREZZA (Valbenazine) New Drug Application For The Treatment Of Tardive Dyskinesia 11/30/2016 10:12:21 AM